The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,130.00
Bid: 12,130.00
Ask: 12,134.00
Change: -26.00 (-0.21%)
Spread: 4.00 (0.033%)
Open: 12,092.00
High: 12,134.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Thursday preview: Astrazeneca to report decline in third quarter sales

Wed, 09th Nov 2016 12:31

(ShareCast News) - Astrazeneca is expected to report a drop in third quarter sales on Thursday after failing to prevent generic drug makers from bringing cheaper rivals of its best-selling medicine Crestor.Analysts expect generic versions of cholesterol fighting drug Crestor will have sent revenue down 1% to $5.87bn in the three months to September, down from $5.95bn a year earlier. The group is expected to reveal net income of $731m, down 5% from the $770m the previous year.Deutsche Bank expects product sales to decline by 10% at a constant exchange rate and core earnings per share to drop about 4%, due to the erosion of Crestor and divestments.Generic versions of heartburn medicine Nexium are also expected to have provided a drag. Astrazeneca is looking to boost sales growth with new drugs, including blood-thinner Brilinta and Tagrisso for lung cancer. Deutsche Bank said Tagrisso should benefit from continued US growth and its recent launch in Japan.The bank also sees Brilinta continuing to show solid growth with US prescriptions increasing 40% year-on-year.Deutsche Bank added that risks to Astrazeneca include failure to deliver cost savings, lower platform sales, pipeline failure and a fall in sales of pipeline drugs.Meanwhile, investors will be looking for an update following's last month's setback on its experimental cancer medicine duralumab. The company suspended recruitment for two large clinical trials on durvalumab while it investigates some instances of bleeding among participants. Thursday 10 November INTERIMS Auto Trader Group , Dairy Crest Group, Halfords Group, Mediclinic International , Mercia Technologies , National Grid, Vedanta Resources INTERIM DIVIDEND PAYMENT DATE British American Inv Trust, Ladbrokes Coral Group, Scisys INTERIM EX-DIVIDEND DATE First Derivatives, Hadrian's Wall Secured Investments, London Security, NB Distressed Debt Investment Fund Limited, NB Distressed Debt Investment Fund Limited Ext Shs, NB Distressed Debt Investment Fund Limited Red Ord, Panther Securities, Whitbread QUARTERLY PAYMENT DATE Merchants Trust QUARTERLY EX-DIVIDEND DATE Boeing Co, BP, Brunner Inv Trust, F&C Commercial Property Trust Ltd., Royal Dutch Shell 'A', Royal Dutch Shell 'B' INTERNATIONAL ECONOMIC ANNOUNCEMENTS Continuing Claims (US) (13:30) Crude Oil Inventories (US) (15:30) Initial Jobless Claims (US) (13:30) Q3 AstraZeneca, Bank Pekao SA GDS (Reg S), Hellenic Telecom Industries SA ADS FINALS Mobile Streams SPECIAL DIVIDEND PAYMENT DATE Photo-Me International AGMS Swallowfield, Target Healthcare Reit Ltd, Tlou Energy Limited (DI), Urals Energy Public Co Ltd. (DI) TRADING ANNOUNCEMENTS Gem Diamonds Ltd. (DI), Howden Joinery Group FINAL DIVIDEND PAYMENT DATE Photo-Me International FINAL EX-DIVIDEND DATE Abcam, Craneware, DX (Group), Go-Ahead Group, JPMorgan Smaller Companies Inv Trust, Jupiter European Opportunities Trust, Revolution Bars Group, Swallowfield
More News
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.